{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:14:52Z","timestamp":1792656892610,"version":"4.5.0"},"reference-count":24,"publisher":"BMJ","issue":"7053","license":[{"start":{"date-parts":[[1996,8,10]],"date-time":"1996-08-10T00:00:00Z","timestamp":839635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[1996,6,20]]},"published-print":{"date-parts":[[1996,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    : To determine the prevalence of continuous use of oral steroids in the general population, the conditions for which they are prescribed, and the extent to which patients taking oral steroids are taking treatment to prevent osteoporosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design<\/jats:bold>\n                    : A cross sectional study with a four year retrospective review of drug treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting<\/jats:bold>\n                    : Eight large general practices in central and southern Nottinghamshire.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Subjects<\/jats:bold>\n                    : A population of 65 786 patients (52% women) registered with a general practitioner during 1995.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : 303 patients (65% (197) women) aged 12-94 years were currently taking \u201ccontinuous\u201d (for at least three months) oral corticosteroid treatment. This figure represents 0.5% of the total population and 1.4% (245\/17 114) of patients aged 55 years or more (1.7% (166\/9601) of women). The usual steroid was prednisolone (97% (294\/303)), the mean dose was 8.0 mg\/day, and the median duration of oral steroid treatment determined in 149 patients was three years. The most common conditions for which continuous oral steroids were prescribed were rheumatoid arthritis (23% (70)), polymyalgia rheumatica (22% (66)), and asthma or chronic obstructive airways disease (19% (59)). Only 41 (14%) of the 303 patients taking oral steroids had received treatment for the prevention of osteoporosis over the past four years. Although 37 of the 41 patients were women, only 10% (18\/181) of the women over 45 years taking continuous oral corticosteroids were currently taking hormone replacement therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : If our figures are typical then they suggest that over 250 000 people in the United Kingdom are taking continuous oral steroids and that most of these are taking no prophylaxis against osteoporosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:boxed-text position=\"float\">\n                      <jats:sec>\n                        <jats:title>Key messages<\/jats:title>\n                        <jats:p>The prevalence of use of oral corticosteroids in a community based population of 65 786 was 0.5%, rising to 1.7% in women aged &gt;\/=55 years<\/jats:p>\n                        <jats:p>The main indications for oral steroids were rheumatoid arthritis, polymyalgia, and asthma or chronic obstructive pulmonary disease<\/jats:p>\n                        <jats:p>Only 14% of patients taking oral steroids had received any treatment to prevent or treat osteoporosis<\/jats:p>\n                        <jats:p>These data suggest that over a quarter of a million people in the United Kingdom are currently taking oral corticosteroids and hence at risk of adverse effects<\/jats:p>\n                      <\/jats:sec>\n                    <\/jats:boxed-text>\n                  <\/jats:p>","DOI":"10.1136\/bmj.313.7053.344","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T19:42:12Z","timestamp":1319744532000},"page":"344-346","source":"Crossref","is-referenced-by-count":277,"title":["Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study"],"prefix":"10.1136","volume":"313","author":[{"given":"L J","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pringle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Tattersfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[1996,8,10]]},"reference":[{"issue":"(suppl)","key":"2025122310445729000_313.7053.344.1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1007\/BF01621853","article-title":"The incidence of hip fracture in Europe.","volume":"1","author":"Kanis","year":"1993","journal-title":"Osteoporosis Int"},{"key":"2025122310445729000_313.7053.344.2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/8756-3282(94)90280-1","article-title":"III. Epidemiology and clinical features of osteoporosis in young individuals.","volume":"15","author":"Khosla","year":"1994","journal-title":"Bone"},{"key":"2025122310445729000_313.7053.344.3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/bmj.309.6961.1069","article-title":"Near fatal chickenpox during prednisolone treatment.","volume":"309","author":"Rice","year":"1994","journal-title":"BMJ"},{"key":"2025122310445729000_313.7053.344.4","unstructured":"Wilson S . Aiming for health in the year 2000: the annual report of the director of public health 1995. Nottingham: Nottingham Health District, 1995."},{"key":"2025122310445729000_313.7053.344.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.1.49"},{"key":"2025122310445729000_313.7053.344.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.10.852"},{"key":"2025122310445729000_313.7053.344.7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM198308043090502","article-title":"Steroid-induced fractures and bone loss in patients with asthma.","volume":"309","author":"Adinoff","year":"1983","journal-title":"N Engl J Med"},{"key":"2025122310445729000_313.7053.344.8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bmj.311.7017.1399","article-title":"Utilisation of hormone replacement therapy by women doctors.","volume":"311","author":"Isaacs","year":"1995","journal-title":"BMJ"},{"key":"2025122310445729000_313.7053.344.9","doi-asserted-by":"publisher","DOI":"10.1136\/thx.46.11.803"},{"key":"2025122310445729000_313.7053.344.10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(88)92721-3","article-title":"Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).","volume":"i","author":"Reid","year":"1988","journal-title":"Lancet"},{"key":"2025122310445729000_313.7053.344.11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0140-6736(88)90566-1","article-title":"Two year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis [letter].","volume":"ii","author":"Reid","year":"1988","journal-title":"Lancet"},{"key":"2025122310445729000_313.7053.344.12","first-page":"1922","article-title":"et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.","volume":"21","author":"Adachi","year":"1994","journal-title":"J Rheumatol"},{"key":"2025122310445729000_313.7053.344.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.4.348"},{"key":"2025122310445729000_313.7053.344.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80345-3"},{"key":"2025122310445729000_313.7053.344.15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1164\/ajrccm\/142.1.104","article-title":"Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study.","volume":"142","author":"Luengo","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"2025122310445729000_313.7053.344.16","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.11.1099"},{"key":"2025122310445729000_313.7053.344.17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jbmr.5650070909","article-title":"Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.","volume":"7","author":"Lukert","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2025122310445729000_313.7053.344.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282404"},{"key":"2025122310445729000_313.7053.344.19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","article-title":"Glucocorticoid-induced osteoporosis: pathogenesis and management.","volume":"112","author":"Lukert","year":"1990","journal-title":"Ann Intern Med"},{"key":"2025122310445729000_313.7053.344.20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2796.1995.tb00868.x","article-title":"Management of corticosteroid-induced osteoporosis.","volume":"237","author":"Eastell","year":"1995","journal-title":"J Intern Med"},{"key":"2025122310445729000_313.7053.344.21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2265.1989.tb03730.x","article-title":"Pathogenesis and treatment of steroid osteoporosis.","volume":"30","author":"Reid","year":"1989","journal-title":"Clin Endocrinol"},{"key":"2025122310445729000_313.7053.344.22","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.6.1640"},{"key":"2025122310445729000_313.7053.344.23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bmj.307.6903.519","article-title":"Steroid osteoporosis.","volume":"307","author":"Spector","year":"1993","journal-title":"BMJ"},{"key":"2025122310445729000_313.7053.344.24","doi-asserted-by":"crossref","unstructured":"Sheldon TA Raffle A Watt I .Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing. BMJ 1996; 312:296\u20137.","DOI":"10.1136\/bmj.312.7026.296"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.313.7053.344","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.313.7053.344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:45:06Z","timestamp":1766515506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.313.7053.344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,8,10]]},"references-count":24,"journal-issue":{"issue":"7053","published-online":{"date-parts":[[1996,8,10]]},"published-print":{"date-parts":[[1996,8,10]]}},"alternative-id":["10.1136\/bmj.313.7053.344"],"URL":"https:\/\/doi.org\/10.1136\/bmj.313.7053.344","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,8,10]]}}}